{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T17:01:57Z","timestamp":1790010117567,"version":"4.0.1"},"reference-count":27,"publisher":"BMJ","issue":"11","license":[{"start":{"date-parts":[[2022,11,2]],"date-time":"2022-11-02T00:00:00Z","timestamp":1667347200000},"content-version":"unspecified","delay-in-days":1,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001826","name":"ZonMw","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021821","name":"Oncode Institute","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/501100021821","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010663","name":"H2020 European Research Council","doi-asserted-by":"publisher","award":["852832"],"award-info":[{"award-number":["852832"]}],"id":[{"id":"10.13039\/100010663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005039","name":"Leids Universitair Medisch Centrum","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/501100005039","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2022,9,13]]},"published-print":{"date-parts":[[2022,11]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The complete response rate of cervical high-grade squamous intraepithelial lesion (cHSIL) patients to imiquimod immunotherapy is approximately 60%. Consequently, many patients are exposed to unnecessary adverse effects of imiquimod. On the other hand, conventional surgical large loop excision therapy is associated with increased risk of premature births in subsequent pregnancies. An in-depth analysis of the cHSIL immune microenvironment was performed in order to identify and develop a predictive biomarker for response to imiquimod, to maximize therapy efficacy and to avoid adverse effects in patients unlikely to respond.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Biopsies of 35 cHSIL patients, before and 10 weeks on imiquimod treatment, were analyzed by two multispectral seven-color immunofluorescence panels for T cell and myeloid cell composition in relation to treatment response. Based on these results a simplified immunohistochemical detection protocol was developed. Samples were scanned with the Vectra multispectral imaging system and cells were automatically identified using machine learning.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The immune microenvironment of complete responders (CR) is characterized by a strong and coordinated infiltration by T helper cells (activated PD1\n                      <jats:sup>+<\/jats:sup>\n                      \/type 1 Tbet\n                      <jats:sup>+<\/jats:sup>\n                      ), M1-like macrophages (CD68\n                      <jats:sup>+<\/jats:sup>\n                      CD163\n                      <jats:sup>-<\/jats:sup>\n                      ) and dendritic cells (CD11c\n                      <jats:sup>+<\/jats:sup>\n                      ) prior to imiquimod. The lesions of non-responders (NRs) displayed a high infiltration by CD3\n                      <jats:sup>+<\/jats:sup>\n                      FOXP3\n                      <jats:sup>+<\/jats:sup>\n                      regulatory T cells. At 10 weeks on imiquimod, a strong influx of intraepithelial and stromal CD4\n                      <jats:sup>+<\/jats:sup>\n                      T cells was observed in CR but not NR patients. A steep decrease in macrophages occurred both in CR and NR patients, leveling the pre-existing differences in myeloid cell composition between the two groups. Based on the pre-existing immune composition differences, the sum of intraepithelial CD4 T cell, macrophage and dendritic cell counts was used to develop a quantitative simplified one color immunohistochemical biomarker, the CHSIL immune biomarker for imiquimod (CIBI), which can be automatically and unbiasedly quantified and has an excellent predictive capacity (receiver operating characteristic area under the curve 0.95, p&lt;0.0001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The capacity of cHSIL patients to respond to imiquimod is associated with a pre-existing coordinated local immune process, fostering an imiquimod-mediated increase in local T cell infiltration. The CIBI immunohistochemical biomarker has strong potential to select cHSIL patients with a high likelihood to experience a complete response to imiquimod immunotherapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jitc-2022-005288","type":"journal-article","created":{"date-parts":[[2022,11,2]],"date-time":"2022-11-02T11:08:40Z","timestamp":1667387320000},"page":"e005288","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":15,"title":["Immune-based biomarker accurately predicts response to imiquimod immunotherapy in cervical high-grade squamous intraepithelial lesions"],"prefix":"10.1136","volume":"10","clinical-trial-number":[{"clinical-trial-number":"nct02917746","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05405270","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9079-0293","authenticated-orcid":false,"given":"Ziena","family":"Abdulrahman","sequence":"first","affiliation":[{"name":"Leiden University Medical Center, Leiden, The Netherlands"},{"name":"Oncode Institute, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasja","family":"Hendriks","sequence":"additional","affiliation":[{"name":"Maastricht University Medical Centre+, Maastricht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnold","family":"J Kruse","sequence":"additional","affiliation":[{"name":"Maastricht University Medical Centre+, Maastricht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonios","family":"Somarakis","sequence":"additional","affiliation":[{"name":"Leiden University Medical Center, Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"J M van de Sande","sequence":"additional","affiliation":[{"name":"Erasmus Medical Center, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heleen","family":"J van Beekhuizen","sequence":"additional","affiliation":[{"name":"Erasmus Medical Center, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jurgen","family":"M J Piek","sequence":"additional","affiliation":[{"name":"Catharina Hospital, Eindhoven, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6122-1024","authenticated-orcid":false,"given":"Noel F C C","family":"de Miranda","sequence":"additional","affiliation":[{"name":"Leiden University Medical Center, Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loes F S","family":"Kooreman","sequence":"additional","affiliation":[{"name":"Maastricht University Medical Centre+, Maastricht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigitte","family":"F M Slangen","sequence":"additional","affiliation":[{"name":"Maastricht University Medical Centre+, Maastricht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6556-0354","authenticated-orcid":false,"given":"Sjoerd H","family":"van der Burg","sequence":"additional","affiliation":[{"name":"Leiden University Medical Center, Leiden, The Netherlands"},{"name":"Oncode Institute, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peggy J","family":"de Vos van Steenwijk","sequence":"additional","affiliation":[{"name":"Maastricht University Medical Centre+, Maastricht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edith M G","family":"van Esch","sequence":"additional","affiliation":[{"name":"Catharina Hospital, Eindhoven, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2022,11,2]]},"reference":[{"key":"2025100312245258000_10.11.e005288.1","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1017\/S0950268814001356","article-title":"Worldwide incidence of cervical lesions: a systematic review","volume":"143","author":"Ting","year":"2015","journal-title":"Epidemiol Infect"},{"key":"2025100312245258000_10.11.e005288.2","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1097\/AOG.0000000000004663","article-title":"Efficacy and long-term outcomes of repeated large loop excision of the transformation zone of the cervix","volume":"139","author":"van de Sande","year":"2022","journal-title":"Obstet Gynecol"},{"key":"2025100312245258000_10.11.e005288.3","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2018.1542426"},{"key":"2025100312245258000_10.11.e005288.4","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1097\/AOG.0000000000004384","article-title":"Topical imiquimod for the treatment of high-grade squamous intraepithelial lesions of the cervix: a randomized controlled trial","volume":"137","author":"Fonseca","year":"2021","journal-title":"Obstet Gynecol"},{"key":"2025100312245258000_10.11.e005288.5","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0b013e31825bc6e8"},{"key":"2025100312245258000_10.11.e005288.6","doi-asserted-by":"crossref","DOI":"10.1016\/j.crwh.2019.e00105","article-title":"Systemic adverse events in imiquimod use for cervical intraepithelial neoplasia - A case series","volume":"21","author":"Wouters","year":"2019","journal-title":"Case Rep Womens Health"},{"key":"2025100312245258000_10.11.e005288.7","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1097\/CJI.0000000000000414","article-title":"Topical imiquimod treatment of high-grade cervical intraepithelial neoplasia (TOPIC-3): a nonrandomized multicenter study","volume":"45","author":"Hendriks","year":"2022","journal-title":"J Immunother"},{"key":"2025100312245258000_10.11.e005288.8","doi-asserted-by":"crossref","first-page":"2914","DOI":"10.1002\/ijc.33168","article-title":"A pre-existing coordinated inflammatory microenvironment is associated with complete response of vulvar high-grade squamous intraepithelial lesions to different forms of immunotherapy","volume":"147","author":"Abdulrahman","year":"2020","journal-title":"Int J Cancer"},{"key":"2025100312245258000_10.11.e005288.9","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000563"},{"key":"2025100312245258000_10.11.e005288.10","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-004346"},{"key":"2025100312245258000_10.11.e005288.11","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1109\/TVCG.2019.2931299","article-title":"ImaCytE: visual exploration of cellular Micro-Environments for imaging mass cytometry data","volume":"27","author":"Somarakis","year":"2021","journal-title":"IEEE Trans Vis Comput Graph"},{"key":"2025100312245258000_10.11.e005288.12","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/s41586-019-1876-x","article-title":"The single-cell pathology landscape of breast cancer","volume":"578","author":"Jackson","year":"2020","journal-title":"Nature"},{"key":"2025100312245258000_10.11.e005288.13","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1016\/j.cell.2020.08.043","article-title":"Multimodal analysis of composition and spatial architecture in human squamous cell carcinoma","volume":"182","author":"Ji","year":"2020","journal-title":"Cell"},{"key":"2025100312245258000_10.11.e005288.14","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2013.10.003"},{"key":"2025100312245258000_10.11.e005288.15","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0497-0"},{"key":"2025100312245258000_10.11.e005288.16","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.2010.083626"},{"key":"2025100312245258000_10.11.e005288.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2012.09.010"},{"key":"2025100312245258000_10.11.e005288.18","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1111\/aji.12030","article-title":"The prevalence of cervical regulatory T cells in HPV-related cervical intraepithelial neoplasia (CIN) correlates inversely with spontaneous regression of CIN","volume":"69","author":"Kojima","year":"2013","journal-title":"Am J Reprod Immunol"},{"key":"2025100312245258000_10.11.e005288.19","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1002756"},{"key":"2025100312245258000_10.11.e005288.20","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-0528.2008.01936.x"},{"key":"2025100312245258000_10.11.e005288.21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2006.11.023"},{"key":"2025100312245258000_10.11.e005288.22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2013\/831907","article-title":"Prognostic significance of immunohistochemical phenotypes in patients treated for high-grade cervical intraepithelial neoplasia","volume":"2013","author":"Origoni","year":"2013","journal-title":"Biomed Res Int"},{"key":"2025100312245258000_10.11.e005288.23","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1720948115"},{"key":"2025100312245258000_10.11.e005288.24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa072685"},{"key":"2025100312245258000_10.11.e005288.25","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-1749"},{"key":"2025100312245258000_10.11.e005288.26","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001326"},{"key":"2025100312245258000_10.11.e005288.27","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-15-0052"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2022-005288","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T19:24:59Z","timestamp":1759519499000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2022-005288"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":27,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2022,11,2]]},"published-print":{"date-parts":[[2022,11]]}},"alternative-id":["10.1136\/jitc-2022-005288"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2022-005288","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11]]}}}